US recommends ‘pause’ for J&J vaccine over blood clot reports

WASHINGTON (AP) — The United States is recommending a “pause” in using the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots.

In a joint statement Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration said they were investigating unusual clots that occurred 6 to 13 days after vaccination.

The clots occurred in veins that drain blood from the brain and occurred together with low platelets.

All six cases were in women between the ages of 18 and 48; there was one death.

The reports appear similar to a rare, unusual type of clotting disorder that European authorities say is possibly linked to another COVID-19 vaccine not yet cleared in the US, from AstraZeneca.

More than 6.8 million doses of the J&J vaccine have been administered in the US, the vast majority with no or mild side effects.

Federally run mass vaccination sites will pause the use of the J&J shot, and states and other providers are expected to follow.

The other two authorised vaccines, from Moderna and Pfizer, make up the vast share of COVID-19 shots administered in the US and are not affected by the pause.

“I’d like to stress these events appear to be extremely rare. However COVID-19 vaccine safety is a top priority,” FDA Acting Commissioner Janet Woodcock said at a news conference.

“We expect it to be a matter of days for this pause.”

A CDC committee will meet Wednesday to discuss the cases and the FDA has also launched an investigation into the cause of the clots and low platelet counts.

CDC’s Dr Anne Schuchat said authorities have not seen similar clots after use of the Pfizer or Moderna vaccines, and that people should continue to get vaccinated with those shots.

The agencies are recommending that people who were given the J&J vaccine who are experiencing severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after receiving the shot contact their health care provider.

J&J said in a statement it was aware of the reports of blood clots, but that no link to its vaccine had been established.

The company also said it is delaying the rollout of its vaccine in Europe as a precaution.

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us @onlinefeedback@gleanerjm.com or editors@gleanerjm.com.